Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
In February 2025, Teva Pharmaceuticals and Alvotech announced ... because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received ...
This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals and ... for shedding from the household contact and transmission to patient.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDIâ„¢for all indicationsmatching the reference product ...
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are ...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
A Baltimore councilman who sought to hold public hearings on the opioid crisis must wait amid an ongoing feud at City Hall.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback